15Mar, 12Press Release, Moscow, March 15th, 2012Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program Co-Invests with Germany’s Public/Private...
10Mar, 14Press Release, Moscow, March 11th, 2014MAXWELL BIOTECH VENTURE FUND’S PORTFOLIO COMPANY HEPATERA COMPLETES ENROLLMENT OF PHASE IIA CLINICAL TRIAL OF...
04Apr, 19MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s...
23Mar, 16Maxwell Biotech Venture Fund’s Portfolio Company Hepatera LLC Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV InfectionHepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label,...
